"Reasonable and necessary" redefined for Medicare
This article was originally published in Clinica
The US Centers for Medicare and Medicaid Services (CMS) is having another stab at defining what criteria it uses for determining whether a product is "reasonable and necessary", and thus fit to be covered by Medicare. But this time, CMS intends to address the subject as a guidance document similar to those issued by the FDA. In 1989 and again in 2000, the agency proposed addressing the issue through regulation, but backed off both times because of industry's objections to the use of cost effectiveness as an important criteria.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.